Rankings
▼
Calendar
BBIO Q4 2024 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena
BBIO
BridgeBio Pharma, Inc.
$14B
Q4 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$6M
+237.1% YoY
Gross Profit
$4M
64.6% margin
Operating Income
-$226M
-3842.7% margin
Net Income
-$265M
-4506.1% margin
EPS (Diluted)
$-1.40
QoQ Revenue Growth
+115.3%
Cash Flow
Operating Cash Flow
-$195M
Free Cash Flow
-$199M
Stock-Based Comp.
$30M
Balance Sheet
Total Assets
$919M
Total Liabilities
$2.4B
Stockholders' Equity
-$1.5B
Cash & Equivalents
$681M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$6M
$2M
+237.1%
Gross Profit
$4M
$1M
+231.1%
Operating Income
-$226M
-$177M
-27.4%
Net Income
-$265M
-$168M
-57.6%
← FY 2024
All Quarters
Q1 2025 →